Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | FASN | P49327 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.32 |
| ▸ | GLI1 | P08151 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.30 |
| ▸ | MMP9 | P14780 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27903631 | 1.00 | MME (0.33) | MMEFASNDPP4PDE7AGLI1 | |
| Oxalic Acid SCHEMBL4114848 | 0.97 | MME (0.32) | MMEFASNDPP4PDE7A | |
| Oxalic Acid SCHEMBL14908944 | 0.95 | DPP4 (0.32) | MMEFASNDPP4PDE7A | |
| Sulfuric Acid SCHEMBL17472893 | 0.94 | MME (0.31) | MMEFASN | |
| SCHEMBL20293628 | 0.89 | MME (0.34) | MMEFASNDPP4PDE7AGLI1 | |
| SCHEMBL20293481 | 0.89 | MME (0.34) | MMEFASNDPP4PDE7AGLI1 | |
| SCHEMBL20328936 | 0.87 | FASN (0.38) | MMEFASNMMP2MMP9MMP1 | |
| SCHEMBL31444622 | 0.85 | BTK (0.36) | — | |
| SCHEMBL4632505 | 0.83 | MME (0.33) | MMEFASNDPP4PDE7AGLI1 | |
| SCHEMBL4632507 | 0.83 | MME (0.33) | MMEFASNDPP4PDE7AGLI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2018-06-28 | — | — | US | disclosed |
| US-9809546-B2 | Process for producing diamine derivative | Chungwha Chemical Synthesis & Biotech Co., Ltd. (TW) | 2017-11-07 | — | — | US | disclosed |
| US-20170260138-A1 | PROCESS FOR PRODUCING DIAMINE DERIVATIVE | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD. (TW) | 2017-09-14 | — | — | US | disclosed |
| EP-2980067-B1 | PROCESSES FOR PREPARING OPTICALLY ACTIVE DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2017-05-17 | — | — | EP | disclosed |
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-2980067-A1 | PROCESSES FOR PREPARING OPTICALLY ACTIVE DIAMINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| EP-1415992-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090105491-A1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1925611-A1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | MME 171/4885FASN 4843/4885DPP4 113/4885 |
| US-20090105491-A1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | TFPI, F2, SERPINC1 | MME 912/4885FASN 2979/4885DPP4 330/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | MME 2012/4885FASN 1014/4885DPP4 3147/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | MME 2012/4885FASN 1014/4885DPP4 3147/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | MME 2012/4885FASN 1014/4885DPP4 3147/4885 |
| US-20170260138-A1 | PROCESS FOR PRODUCING DIAMINE DERIVATIVE | DDT, ODC1, DDC | MME 1255/4885FASN 1730/4885DPP4 1290/4885 |
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | VKORC1, CYP2C9, VKORC1L1 | MME 2026/4885FASN 1917/4885DPP4 2271/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | MME 1985/4885FASN 1059/4885DPP4 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.